(Q37503337)

20 August 2017

1 reference

title

Serine protease inhibitors as anti-hepatitis C virus agents (English)

1 reference

20 August 2017

1 reference

2

Jörg Timm

1 reference

20 August 2017

Markus Reiser

1

1 reference

20 August 2017

1 June 2009

1 reference

Expert Review of Anti-infective Therapy

20 August 2017

1 reference

20 August 2017

7

1 reference

20 August 2017

537-547

1 reference

20 August 2017

5

1 reference

Interferon-based therapy for chronic hepatitis C: current and future perspectives

20 August 2017

1 reference

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin

21 January 2018

1 reference

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

Unravelling hepatitis C virus replication from genome to function

21 January 2018

1 reference

From structure to function: new insights into hepatitis C virus RNA replication

21 January 2018

1 reference

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy

21 January 2018

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

21 January 2018

1 reference

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

21 January 2018

1 reference

Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.09.30

1 reference

20 August 2017

1 reference

PubMed ID

19485794